A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Sun Ah Park*, Ju-Hee Kang*, Eun-Suk Kang†, Chang-Seok Ki‡, Jee Hoon Roh§, Young Chul Youn**, Seong Yoon Kim*, Sang Yun Kim†

*Department of Neurology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
†Department of Pharmacology & Clinical Pharmacology, Inha University School of Medicine, Incheon, Korea
‡Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
§Departments of Neurology and Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
**Department of Neurology, Chung-Ang University Hospital, Seoul, Korea
†Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea
‡Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Cerebrospinal fluid (CSF) can provide vital information about pathological processes occurring in the brain. In particular, the CSF concentrations of Aβ42, Tau, and pTau181 are useful for the early diagnosis of Alzheimer’s disease (AD). However, many studies have demonstrated that confounding factors related to the preanalytical processing of CSF can seriously influence measurements of these AD biomarkers. It is therefore important to develop a standardized protocol for the acquisition and handling of CSF, particularly with regard to the types of tube used for collection and storage, the proper aliquot volume, blood contamination, and the number of tube transfers and freeze-thaw cycles, because these aspects of the procedure have been shown to affect AD biomarker measurements. A survey of the impact of several individual preanalytical procedures on the measurement of AD biomarkers in CSF was conducted for this review article, and the implications of the differences among them are discussed. Furthermore, following a review of the procedures used in Korean and international biomarker laboratories, a consensus was reached among a cooperative Korean multicenter research group regarding a standardized protocol for the analysis of AD biomarkers in CSF. All efforts were made to be stringent regarding the controversial issues associated with this protocol, thus minimizing the confounding influence of various factors on current investigations using established AD biomarkers and on future studies using novel biomarkers of AD and other neurodegenerative disorders.

Key Words Alzheimer’s disease, biomarker, cerebrospinal fluid, protocol, standardization.

INTRODUCTION

There is a significant amount of evidence to support using cerebrospinal fluid (CSF) biomarkers to more accurately diagnose Alzheimer’s disease (AD) and AD-related mild cognitive impairment (MCI) in the research setting. For example, a decrease in CSF levels of Aβ42 is strongly correlated with an increased Aβ burden in the brain, and an increase in the levels of tau and pTau181 are thought to reflect neurodegeneration and tangle pathology, respectively. Since AD neuropathology develops much earlier than the expression of its clinical symptoms, measurement of AD biomarkers may be very useful for the early diagnosis of AD. In practice, the combined ratio of Aβ42 and tau proteins strongly predicts the progression of AD in subjects with MCI, and as tau and pTau levels increase, the progression of dementia becomes more rapid. This is important because a more accurate diagnosis of AD during the early stages increases the probability of AD patients overcoming this disease. In addition, the lessons learned from the failures of previous clinical trials that led to earlier administrations of potentially disease-modifying treatments using established AD biomarkers and on future studies using novel biomarkers of AD and other neurodegenerative disorders.

Received July 2, 2014
Accepted October 28, 2014

Copyright © 2015 Korean Neurological Association
agents prior to the onset of clinical symptoms stand out as a major concern in current drug trials. Thus, the utility of CSF biomarkers for the accurate diagnosis of AD extends beyond pure academic interest and includes a number of clinical applications.

Recent preliminary validations performed in Korea have demonstrated that the t>Tau/Aβ42 and p>Tau/Aβ42 ratios in CSF are highly sensitive and specific for the diagnosis of AD. The trial was conducted to assess the potential of enzyme-linked immunosorbent assay (ELISA) methods to measure AD biomarkers in CSF to be approved for their use from the New Health Technology Assessment of Ministry for Health, Welfare & Family Affairs of Korea (http://neca.re.kr/nHTA/index.jsp). However, before CSF AD biomarker assays can be adopted unconditionally as a reliable tool in clinical practice, there must be a quality control program in place for the individual protocol steps to further improve the reliability and accuracy of these measurements; consistent reference and cutoff values for the AD biomarkers commonly used in Korea must also be established. International attempts to accomplish these goals began in 2009, and the first step toward reducing the variability among procedures in different labs involved sharing the individual protocols to identify and removing confounding factors from the preanalytical process. One of the main reasons interlaboratory variability persists is inconsistency in the acquisition and handling of samples. Thus, with the aim of establishing a standardized protocol across Korean laboratories, we have conducted a thorough review of the various confounding factors discussed in previous reports, and suggested a consensus on the individual steps for the preanalytical process related to the measurement of AD biomarkers in CSF.

Six research centers with experience and continued interest in the analysis of AD biomarkers in CSF were involved in the creation of this consensus. The opinions of the participants were obtained regarding the individual steps of our own protocols and those available from international biomarker laboratories or networks, including the Alzheimer’s Disease Neuroimaging Initiative (ADNI; http://www.alzforum.org/sites/default/files/protocol_Biodfluid_Sample_Collection_Protocol_for_ADNI_0.pdf), the Alzheimer’s Association (AA; http://www.alzforum.org/sites/default/files/protocol_Flow_Champ_for_Lumbar_Puncture_CSF_Processing_0.pdf), Washington University (http://www.alzforum.org/sites/default/files/protocol_CSF_sample_collection.pdf), the Alzheimer’s Biomarker Standardization Initiative (ABSI), the European Network for Biomarkers (ENB), and the recent updates of the last two protocols, which focus on the biomarkers of AD and Parkinson’s disease (PD) (Table 1). If any inconsistencies were found between current and previously used protocols, they were discussed prior to reaching the final consensus. Most of the identified inconsistencies were resolved using a set of higher standards required by more recent protocols, with the hope that the measurements of established and future candidate AD biomarkers in preserved CSF samples would not be influenced significantly.

THE USE OF NEUROIMAGING PRIOR TO LUMBAR PUNCTURE (LP)

When performing a lumbar puncture (LP) to collect CSF, the presence of a high intracranial pressure may result in fatal cerebellar or transtentorial herniation. Thus, to exclude the possibility of a mass lesion or elevated intracranial pressure, it is necessary to obtain any brain images at least 1 year prior to the LP. Furthermore, if newly developed headaches or focal neurological signs are present, follow-up neuroimaging should be considered prior to performing an LP. Increased bleeding risk, low platelet count, or the use of anticoagulants would generally prohibit performing an LP; but the continuation of antiplatelet medications is not a contraindication for LP according to the ABSI protocol. All procedures need to be performed by experienced physicians.

NECESSITY OF FASTING PRIOR TO LP

The review of the various protocols used by international laboratories revealed controversy regarding the issue of fasting. The ADNI and Washington University require at least 6 hours of fasting (and preferably overnight) prior to an LP, while the ABSI does not. A single Korean study indicated that fasting is mandatory, but others indicated that it was not. Only one study involving a small number of healthy subjects has examined the effects of fasting on Aβ concentrations. Even though that study was performed using plasma rather than CSF, the consistency of Aβ levels in CSF (irrespective of fasting) is assumed based on the results of this plasma study. However, this evidence is not sufficient to clearly exclude the impact of fasting on the levels of Aβ42, tau proteins, or future candidate biomarkers in CSF. Thus, fasting for a minimum of 6 hours (and preferably overnight) is recommended prior to an LP procedure. Furthermore, if fasting prior to CSF sampling is impossible, the time between the last meal and the LP procedure should be noted.

APPROPRIATE TIMING OF THE LP

Diurnal fluctuations in Aβ42 levels of up to fourfold have
Table 1. Comparison of the previous protocols used for the preanalytical standardization of CSF AD biomarkers

| SchBC | SNUBH-ChU | ADNI | AA | Washington University | ENB | ABSI | Recent update for AD/PD CSF biomarkers
|-------|-----------|------|----|-----------------------|-----|------|----------------------------------------
| Performing neuroimaging before LP | Yes | Yes | Yes | Yes | Yes | Not mentioned | Yes | Not mentioned |
| Fasting before LP | Required (overnight) | Not required | Required (minimum 6 h) | Not required | Required (overnight) | Not mentioned | Not required | pTau, tTau |
| Timing of LP | 8–10 a.m. | 8–12 a.m. | Morning | 8–12 a.m. | 8 a.m. | Standardized time | Anytime | Anytime |
| Location | L3–L5 | L3–L5 | L3–L5 | L3–L5 | L3–L5 | L3–L5 | L3–L5 |
| Puncture needle | 21 G, atraumatic | 22 G, any type | 24 G, atraumatic. Cutting-edge needle is possible (≥20 G) | 22 G, any type (with atraumatic technique) | 22 G, atraumatic (cat. 001151-30C, Pajunk) | Atraumatic (Sprotte or Whitacre needle) | 22 G, preferably atraumatic |
| Drainage method | Drip | Drip | Drip or syringe drainage by 5 mL when using 24-G atraumatic needle | Not mentioned | Drip | Not mentioned | Not mentioned | Not mentioned |
| CSF routine analysis | Yes, using initial 1–2 mL | No | Yes, using the subsequent 2 mL after discarding initial 1–2 mL | Yes, using the subsequent 1–2 mL, after discarding initial 0.5–1 mL | Not mentioned | Yes, using initial 1–2 mL | No | Not mentioned |
| Traumatic puncture | Discard all if bloody | Initial part should be discarded if bloody, only clear part should be collected | Always initial 1–2 mL (or more if needed) should be discarded, only clear part should be collected | Always initial 0.5–1 mL (or more if needed) should be discarded, only clear part should be collected | Initial part should be discarded if bloody, only clear part should be collected | Do not proceed further, when more than 500 RBC/µL | Initial part should be discarded if bloody, only clear part collected and then centrifuged within 2 h | Do not proceed further when more than 50 RBC/µL |
| Collection volume | 5 mL | 10–12 mL | 18 mL | 10–12 mL | Up to 30 mL | 10 mL | ≥1.5 mL | 12 mL |
| Type of collection tubes | Conical PP tube (cat. 352098, BD Falcon) | PP tube | PP tube | PP tube | Conical PP tube (cat. 352098, BD Falcon) | PP tube | PP tube | PP tube |
Table 1. Comparison of the previous protocols used for the preanalytical standardization of CSF AD biomarkers (continued)

| SCHBC<sup>a</sup> | SNUBH–CHU<sup>b</sup> | ADNI<sup>c</sup> | AA<sup>+</sup> | Washington University<sup>d</sup> | ENB<sup>e</sup> | ABSI<sup>f</sup> | Recent update for AD/PD CSF biomarkers<sup>g</sup> |
|-----------------|-------------------------|-----------------|-----------|-----------------------------|-------------|------------|-----------------------------------|
| Type of storage tube | 1-mL PP tube with screw-cap (cat. 366656, Thermo) | 1.5-mL PP tube | PP tube from Sarstedt | 2-mL PP tube with screw cap (cat. 430915, Corning) | Small-volume PP tube with screw cap | Standardized small-volume PP tube | Small-volume PP tube |
| Additional transfer of CSF | No | No | One more (for shipping) | No | One more (for inverting) | No | Not mentioned |
| Permitted stay at RT | 1 h | Not mentioned | 0 h | Up to 2 days | 0 h | 1–2 h | Up to 5 days for Aβ42, pTau, tTau <5 days at 4°C, or preferably freeze as soon as possible |
| Necessity of centrifugation | 4,000×g for 10 min at 4°C | 1,500×g for 10 min at RT | No | 2,000×g for 5 min at 4°C | 400×g or 2,000×g (depending on necessity of cell storage for 10 min at RT) | No (except for traumatic tap: 2,000×g for 10 min at RT) | 2,000×g for 10 min at RT |
| Aliquot volume | 700 µL in 1-mL PP tube | 1 mL in 1.5-mL PP tube | 500 µL in PP tube | Not mentioned in detail | 500 µL in 2-mL PP tube | 0.1–1 mL depending on total volume of PP tube, ≥75% tube filling | Standardized small-volume PP tube, ≥50% tube filling |
| Freezing method | Put in deep freezer (-80°C) | Put in deep freezer (-80°C) | First place in dry ice, then deep freezer (-80°C) | Put in deep freezer (-80°C) or liquid nitrogen | Put in deep freezer (-80°C) | Put in deep freezer (-80°C) | Put in deep freezer (-80°C) |
| Freeze/thaw cycles (n) | 1 | 1 | 1 | 2 or 2 | 1 | 1 | 1 or 2 |

<sup>a</sup>http://www.alzforum.org/sites/default/files/protocol_Biofluid_Sample_Collection_Protocol_for_ADNI_0.pdf, <sup>b</sup>http://adni.loni.usc.edu/wp-content/uploads/2008/07/adni2-procedures-manual.pdf, <sup>c</sup>http://www.alzforum.org/sites/default/files/protocol_Flow_Chart_for_Lumbar_Puncture_CSF_Processing_0.pdf, <sup>d</sup>http://www.alzforum.org/sites/default/files/protocol_CSF_sample_collection.pdf. <sup>e</sup>AA: Alzheimer’s Association, ABSI: Alzheimer’s Biomarker Standardization Initiative, AD: Alzheimer’s disease, ADNI: Alzheimer’s Disease Neuroimaging Initiative, CHU: Chung-Ang University, CSF: cerebrospinal fluid, ENB: European Network for Biomarkers, LP: lumbar puncture, PD: Parkinson’s disease, PP: polypropylene, RBC: red blood cells, RT: room temperature, SCHBC: Soonchunhyang University Bucheon Hospital, SNUBH: Seoul National University Bundang Hospital.
been demonstrated,23 highlighting the importance of the time at which the LP required to sample the CSF is performed. However, studies involving elderly populations did not find any significant time-dependent alterations in Aβ42 levels associated with LP.21 The ABSI protocol and its recent updates do not recommend a specific time period for CSF drainage,24,25 but AA protocols suggest an optimal LP procedure time of between 8:00 a.m. and noon (http://www.alzforum.org/sites/default/files/protocol_Flow_Chart_for_Lumbar_Puncture_CSF_Processing_0.pdf), and the ADNI recommends consistency in the timing of LP examinations (http://adni.loni.usc.edu/wp-content/uploads/2008/07/adni2-procedures-manual.pdf). To avoid remarkable diurnal variations in Aβ levels in the CSF, Washington University consistently performs LP procedures at 8:00 a.m.30 Experimental studies using microdialysis procedures in animal models have demonstrated an enhanced clearance of brain metabolites, including Aβ, during sleep,30,36 indicating that diurnal fluctuations in protein levels are an important issue to consider. Thus, it is reasonable to recommend a consistent time range within which the LP procedure should be performed in standardized protocols. Considering the usual schedule of clinical practice in Korea, between 8:00 a.m. and noon has been suggested as a reasonable time period during which to conduct LP procedures. However, exceptions are permitted. Further studies are recommended in order to establish the optimum timing of the LP procedure.

**PUNCTURE NEEDLE TYPE FOR LP**

The size and type of needle used for LP have not been considered previously as being significant confounding factors when investigating AD biomarker levels in CSF.24 However, it is important to recognize this issue in order to avoid LP-related complications and traumatic punctures.20,26 For example, postpuncture headaches and other complications may be highly problematic in elderly patients, especially those with cognitive decline, and the use of anatraumatic needle would probably be beneficial.20 The use of a 22- to 24-G Sporette atraumatic needle is recommended, in agreement with protocols used at most international biomarker laboratories23,25 (http://www.alzforum.org/protocols). A conventional cutting-edge needle thinner than 19 G may also be used, but requires a cautious technique, including assuring that the bevel and longitudinal directions of the dura mater fibers are parallel30 and instructing patients to avoid strenuous physical activity for at least 24 hours after the LP procedure.30

**CSF DRAINAGE**

Natural drainage of the CSF during the LP procedure is recommended. However, if a 24-G atraumatic needle is used, then the CSF sample can be obtained using repetitive 5-mL sterile syringes, as in the ADNI protocol (http://www.alzforum.org/sites/default/files/protocol_Biofluid_Sample_Collection_Protocol_for_ADNI_0.pdf). A sterile polypropylene syringe of the type offered by a standardized manufacturer should be used.

**THE NEED FOR ROUTINE ANALYSIS**

Cell counts and analyses of total protein and glucose levels using the initially obtained 2-mL CSF sample are required by the protocols of the ADNI, AA, and ENB.21 Although these requirements are not specifically mentioned in other protocols,24,25,29 the routine adoption of this procedure would be beneficial given that blood contamination has been a concern in most studies (as discussed in the following section). Moreover, cell counts and basic chemical profiles should be available as a reference for future investigations. For example, CSF levels of α-synuclein levels, a biomarker for PD, are dramatically influenced by contamination of the CSF by blood.31,42

**TRAUMATIC-PUNCTURE ISSUES**

Contamination of the CSF by blood is a major concern because it may affect analyses of CSF biomarker concentrations.23-25 Although the presence of up to 5,000 red blood cells per microliter in the CSF was found to not significantly alter the levels of Aβ42, which remained within the range of intra-individual variance,24 substantial levels of protein-binding proteins and proteases present in the plasma could potentially affect the measurements of other AD-related biomarkers, such as tau proteins and other metabolites.43 Thus, it is recommended that blood-contaminated CSF be discarded until the sample is clear, as instructed by most international protocols.23,25 Furthermore, in the case of a traumatic LP, the immediate centrifugation of CSF is recommended to remove nonvisible blood cells from the fluid.

**VOLUME OF COLLECTED CSF**

There is controversy regarding the appropriate volume of CSF that should be collected for biomarker analysis. The differences in sampling volumes used among laboratories are worrisome, because it is possible that rostrocaudal gradients influence biomarker concentrations. Accordingly, previous protocols have recommended that the collection of at least
12 mL of CSF is appropriate. A small volume of CSF may potentially represent only the contents of the lumbar dural sac, but evaluation of a series of continuous 10-mL CSF samples revealed that Aβ42 levels were not significantly different among the fractions. Although no variation in Aβ42 CSF levels has been observed along the spinal cord, other proteins, and especially albumin, neurotransmitters, and apolipoprotein, do vary. Unpublished data using the ABSI protocol recommend the collection of at least 1.5 mL of CSF, while the ADNI protocol and Washington University suggest collection volumes of 18 and 30 mL, respectively. The most recent consensus for the appropriate CSF volume to be collected for preanalytical processing of AD and PD biomarkers recommends a standardized volume of 12 mL. Similarly, it is suggested here that the CSF sampling volume be standardized to 10–12 mL for clinical laboratory research.

**TYPES OF COLLECTION AND STORAGE TUBES**

The types of tube used to collect and store samples for AD biomarker analysis may influence the concentrations of Aβ42 and tau proteins. Polystyrene and glass tubes have been shown to markedly decrease the concentrations of Aβ42, pTau181, and tTau; consequently, recent protocols have employed polypropylene tubes. However, significant differences in Aβ42 and pTau181 levels have been observed depending on the vendor supplying the polypropylene tubes. These differences demonstrate the necessity of consistency when using these tubes, especially since numerous commercially available polypropylene tubes are made of copolymers rather than pure polypropylene. Accordingly, it is suggested that 15-mL sterile centrifuge tubes with a conical bottom (cat. #352096, BD Falcon, Bedford, MA, USA; or other standardized tubes) should be used as the standard collection tube, as described previously. Similarly, the standard storage tubes should be 500-μL sterile polypropylene tubes with screw caps (cat. 72.730.006 or 72.730.005, Sarstedt, Nürnbrecht, Germany; or other standardized tubes), as described in the protocols from ADNI and other laboratories.

**NUMBER OF CSF TRANSFERS BETWEEN TUBES**

Based on concerns regarding rostrocaudal gradient-dependent variations in AD biomarkers, the Washington University protocol suggests transferring the CSF to new collection tubes following centrifugation to mix the CSF (http://www.alzforum.org/sites/default/files/protocol_CSF_sample_collection.pdf). According to the ADNI protocol, the initially collected CSF should be transferred to two shipping tubes, and a biorepository core laboratory should vortex the CSF thoroughly and aliquot it for storage. However, a mean decrease in Aβ42 levels of 28.6% has been observed following transfer of CSF between tubes, with the most significant change being seen after the initial transfer. In the case of tTau, the transfer-induced decrease in concentration is negligible. Direct transfer of CSF from the collection tube into individual 0.5-mL frozen tubes is recommended for long-term storage.

**STORAGE OF SAMPLES AT ROOM TEMPERATURE PRIOR TO FREEZING**

The CSF levels of Aβ42, tau, and pTau are reportedly stable at room temperature for up to 14 days, although another study found these protein levels to be constant for only up to 5 days. Accordingly, the ABSI protocol for evaluating AD biomarkers permits storage of CSF at room temperature for up to 5 days before its delivery to a core analysis center for freezing. However, the stability of other proteins is not certain. The level of a candidate biomarker for synucleinopathy, α-synuclein, is reduced by up to 40% following storage at 4°C for 4 days, and analyses of this protein using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry revealed significant alterations in 6 of the 91 peaks following storage at room temperature for 4 hours. Several amino acids and their metabolites are also vulnerable to decay during the time period prior to freezing, even if the delay is only 30–120 min, but these changes can be mitigated by the removal of cells via centrifugation. If only Aβ42 and tau proteins are to be analyzed, then delayed freezing may be possible, but the future validation of novel biomarkers for AD diagnosis may require shorter time delays prior to freezing, as suggested by the protocols of the ADNI, Washington University, and ENB, as well as the present authors. Thus, a delay of no more than 4 hours at room temperature prior to deep freezing is suggested, and it is recommended that the time period before freezing is recorded for each individual sample.

**NECESSITY OF CENTRIFUGATION**

The ABSI protocol recommends centrifugation only in the case of a traumatic spinal tap, while the current ADNI protocol does not include centrifugation. The instability of proteomic analytes due to the time delay before freezing is more profound in noncentrifuged samples. Thus, the use of centrifugation to remove nonvisible blood components prior to long-term storage may be reasonable. The most recent protocols for the analysis of AD and PD biomarkers in CSF include centrifugation as a mandatory step because α-synuclein
levels are susceptible to blood contamination;\textsuperscript{25-27} likewise, the current instructions of the INNOTEST ELISA kit [Fujirebio Europe (previously Innogenetics), Gent, Belgium] specify centrifugation. In addition, different laboratories conduct centrifugation under varying conditions, especially with respect to temperature (room temperature\textsuperscript{23-25} versus 4°C\textsuperscript{26}). Centrifugation does not increase the temperature of the CSF sample.\textsuperscript{23} Thus, centrifugation at 2,000 x g for 10 min at room temperature is reasonable based on previous protocols\textsuperscript{23,25} and the instructions provided by the kit manufacturer.

**ALIQUOT VOLUME AND LABELING OF THE FROZEN TUBES**

Concerns regarding freeze evaporation and surface adsorption have been raised; as a result, some protocols specify the aliquot volume occupy at least 50\%\textsuperscript{24} or 75\%\textsuperscript{23,25} of the tube volume, and the use of a screw cap (http://www.alzforum.org/sites/default/files/protocol_CSF_sample_collection.pdf). Moreover, additional confounding factors related to aliquot volume have been identified recently. Levels of Aβ42, but not t-Tau or p-Tau, change significantly depending on the storage volume of the CSF samples.\textsuperscript{55} The high hydrophobicity of Aβ42 may increase surface adsorption to the vessel wall, but addition of the Tween-20 detergent to the initial CSF samples prior to aliquoting diminishes the adsorption of Aβ42 into polypropylene tubes.\textsuperscript{55} However, this manipulation step has yet to be adopted by established protocols. Thus, it is important to standardize the aliquot volume and the type of tubes used for long-term freezing. The use of 500-μL polypropylene tubes with screw caps (500 μL; cat. 72.730.006 or 72.730.005, Sarstedt) to aliquot 400 μL of CSF and immediate freezing of the samples at -80°C are recommended. According to the INNOTEST kit, the total volume of CSF per aliquot required for measurements of Aβ42, t-Tau, and p-Tau (with duplicates) is 350 μL. Thus, a fresh aliquot volume of 400 μL is sufficient for the measurement of these three biomarkers.

Subsequently, written labels that include the coded sample numbers and the serial aliquot number of the total numbers of aliquot for each CSF sample (e.g., 3/20, the 3rd of 20 aliquots) are recommended on the surface of frozen tubes. Water-resistant materials should be used for labeling.

**NUMBER OF PERMITTED FREEZE-THAW CYCLES PRIOR TO ANALYSIS**

The importance of minimizing the number of freeze-thaw cycles is clear, and accordingly most protocols limit the num-

---

**Table 2. The consensus regarding the preanalytical processing of CSF AD biomarkers**

| Key subject                  | Recommendation                                                                                                                                 |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Neuroimaging prior to LP     | Yes, within 1 year                                                                                                                          |
| Necessity of fasting         | Preferably overnight or at least 6 h. If not, record the time of the last meal*                                                             |
| Timing of LP*                | 8:00 a.m. to noon (preferably closer to 8:00 a.m.). Exceptions are permitted                                                               |
| Location                     | L3–L5                                                                                                                                         |
| Puncture needle              | Preferably a 22- to 24-G atraumatic needle. A conventional cutting-edge needle thinner than 19 G may also be used, but requires caution |
| Drainage method              | Drip or syringe drainage of 5 mL using a 24-G atraumatic needle                                                                             |
| CSF routine analysis         | Yes, using an initial volume of 1–2 mL                                                                                                       |
| Traumatic puncture           | Initial samples should be discarded if bloody, with only the clear part collected and then centrifuged immediately                          |
| Collection volume            | 10–12 mL                                                                                                                                       |
| Type of collection tube      | 15-mL centrifuge tubes, conical bottom, sterile (cat. 352096, BD Falcon; or other standardized tubes)                                         |
| Type of storage tube         | 500-μL PP tubes with a screw cap (cat. 72.730.006 or 72.730.005, Sarstedt; or other standardized tubes)                                    |
| Additional transfer of CSF   | Not permitted                                                                                                                                |
| Permitted storage at RT      | Up to 4 h                                                                                                                                      |
| Necessity of centrifugation  | 2,000 x g for 10 min at RT                                                                                                                   |
| Aliquot volume               | 400 μL in a 500-μL PP tube                                                                                                                   |
| Freezing*                    | Deep freezer (-80°C)                                                                                                                         |
| Freeze/thaw cycles           | One                                                                                                                                           |

*Record the time.
CSF: cerebrospinal fluid, LP: lumbar puncture, RT: room temperature.
CONCLUDING REMARKS

There is a better understanding of the biological mechanisms underlying the clinical manifestations of AD than perhaps those underlying other neurodegenerative disorders, and AD-related biomarkers therefore have implications for clinical practice. The study of these markers in CSF has thus become more than just of academic interest. The general acceptance of Aβ42, pTau, and tTau levels in CSF as biomarkers for the early diagnosis of AD was evident after their inclusion in the new diagnostic criteria for AD established by the National Institute on Aging and the Alzheimer’s Association.4

With regard to the development of disease-modifying therapies in the future, the early diagnosis of AD is of prime importance for therapeutic interventions. Even before that time, the precise diagnosis of AD during the early stages is beneficial for initiating aggressive and appropriate available treatment. Currently, the measurements of pTau181 in CSF using ELISA have been accepted as a new health technology in Korea (http://neca.re.kr/nHTA/index.jsp). Although the diagnostic cutoff values for Aβ42, pTau181, and tTau in CSF for the diagnosis of AD have been established in one Korean laboratory,21 the direct application of these values by other institutions should be approached with caution. There is distinct interlaboratory variability in the measurement of AD biomarkers internationally among biomarker laboratories, especially for Aβ42.22 Standardization of the preanalytical sampling and handling protocols is necessary to ameliorate this variability (Table 2), and its importance cannot be overemphasized. Thus, in the present article we have made a concerted effort to review, assess, and suggest the most reliable procedures for avoiding any disturbances during the preanalytic process. The analysis of AD biomarkers in CSF will hopefully be conducted under the supervision of a quality control program according to this cooperative protocol, to achieve the ultimate goal of a qualified and valid AD biomarker in CSF that can be assessed with high reliability in Korea.

Conflicts of Interest

The authors have no financial conflicts of interest.

Acknowledgements

This study was supported by grants from the Korean Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (H109C1311, H110C2020, and H112C0713), and by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (Medical Research Center No. 2014009392).

REFERENCES

1. Vanderstichele H, De Vreeze K, Blennow K, Andreasen N, Sindic C, Ivanou A, et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer’s disease and dementia with Lewy bodies. Clin Chem Lab Med 2006;44:1472-1480.

2. Shaw LM, Vanderstichele H, Knapik-Czaja M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 2009; 65:403-413.

3. Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2009;116:203-212.

4. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263-269.

5. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:270-279.

6. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010;9:1118-1127.

7. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, et al. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement 2011;7:133-141.

8. Grimmer T, Riemenschneider M, Försöl H, Henriksen G, Klunk WE, Mathis CA, et al. Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009;65:927-934.

9. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652-656.

10. Leow AD, Yanovsky I, Parikhshak N, Hua X, Lee S, Toga AW, et al. Alzheimer’s disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 2009;45:645-655.

11. Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 2006;129(Pt 11):3035-3041.

12. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6.
13. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol* 2013;12:207-216.

14. Van Sj, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, et al. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. *Neurology* 2013;80:1124-1132.

15. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. *Arch Neurol* 2002;59:1729-1734.

16. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. *Arch Gen Psychiatry* 2012;69:98-106.

17. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Mintlon H. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. *Lancet Neurol* 2006;5:228-234.

18. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. *Arch Neurol* 2009;66:638-645.

19. Tabaradu E, Leman JP, Milor AM, Rousse JM, Barrière G, Tarty M, et al. Alzheimer CSF biomarkers in routine clinical setting. *Acta Neurol Scand* 2012;125:418-423.

20. Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease. *Nat Rev Drug Discov* 2013;12:324.

21. Park SA, Kim JH, Kim JM, Kim TE, Kim YJ, Lee DH, et al. Preliminary study for a multicenter study of Alzheimer’s disease cerebrospinal fluid biomarkers. *Dement Neurocog Disord* 2013;12:1-8.

22. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Obeiro P, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium. *Alzheimers Dement* 2013;9:137-140.

23. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. *Neurology* 2009;73:1914-1922.

24. Vanderstichele H, Bihl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. *Alzheimers Dement* 2012;8:65-73.

25. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. *Biomark Med* 2012;6:419-430.

26. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer’s Association quality control program. *Alzheimers Dement* 2013;9:251-261.

27. Hampel H, Lista S, Teipel SJ, Garaci F, Nisticò R, Blennow K, et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer’s disease: a long-range point of view beyond 2020. *Biochem Pharmacol* 2014;88:426-449.

28. Lee EH, Youn YC, Park KY, Min JH, Kwon OS, Lee HO, et al. The effect of acetylcholine esterase inhibitor on cerebrospinal fluid beta-amyloid 1-42 and phosphorylated tau protein in Korean Alzheimer’s disease patients: preliminary study. *J Korean Neurol Assoc* 2008;26:224-230.

29. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in non-demented older adults. *Arch Neurol* 2007;64:343-349.

30. Evans RW. Complications of lumbar puncture. *Neur Clin* 1998;16:83-105.

31. Lim TS, Choi JY, Park SA, Youn YC, Lee HY, Kim BG, et al. Evaluation of coexistence of Alzheimer’s disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers. *BMC Neurol* 2014;14:66.

32. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsäter H, Anckarsäter R, et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. *Int J Alzheimers Dis* 2010;2010 pii: 986310.

33. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. *Neurology* 2007;68:666-669.

34. Moghekar A, Goh J, Li M, Albert M, O’Brien RJ. Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort. *Arch Neurol* 2012;69:246-250.

35. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolic clearance from the adult brain. *Science* 2013;342:373-377.

36. Rohl JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, et al. Disruption of the sleep–wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer’s disease pathology. *Sci Transl Med* 2013;5. 150ra122.

37. Strupp M, Schueler O, Straube A, Von Stuckrad-Barre S, Brandt T. “Atraumatic” Sprotte needle reduces the incidence of post-lumbar puncture headaches. *Neurology* 2001;57:2310-2312.

38. Tung CE, So YT, Lansberg MG. Cost comparison between the atraumatic and cutting lumbar puncture needles. *Neurology* 2012;78:109-113.

39. Arendt K, Dementiaahl BM, Wingerchuk DM, Camann W. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? *Neurologist* 2009;15:17-20.

40. Ahmed SV, Jayawarna C, Jude E. Post lumbar puncture headache: diagnosis and management. *Postgrad Med J* 2006;82:713-716.

41. Hong Z, Shi M, Chung KA, Quinn JJ, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. *Brain* 2010;133(Pt 3):713-726.

42. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid β-amyloid-1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naïve patients with early Parkinson disease. *JAMA Neurology* 2013;70:1277-1287.

43. You JS, Gelainova V, Kniernman MD, Wittmann FA, Wang M, Hale JE. The impact of blood contamination on the proteome of cerebrospinal fluid. *Proteomics* 2005;5:290-296.

44. Blennow K, Fredman P, Wallin A, Gottfries CG, Längström G, Svennerholm L. Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. *Eur Neurol* 1993;33:126-128.

45. Blennow K, Wallin A, Gottfries CG, Månsson JE, Svennerholm L. Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. *J Neurotransm Park Dis Dement Sect* 1995;5:5-15.

46. Simonsen AH, Bech S, Laursen I, Salvesen L, Wingé P, Waldemar G, et al. Proteomic investigations of the ventriculo-lumbar gradient in human CSF. *J Neurosci Methods* 2010;191:244-248.

47. Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fisser M, et al. Effect of sample collection tubes on cerebrospinal fluid iod concentrations of tau proteins and amyloid beta peptides. *Clin Chem* 2006;52:332-334.

48. Pica-Mendez AM, Tänen M, Dallof A, Tanaka W, Laterza OE. Non-specific binding of Aβ42 to polypropylene tubes and the effect of Tween 20. *Clin Chem Acta* 2010;411:1833.

49. Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Risk of Alzheimer’s disease biological misdiagnosis linked to cerebrospinal collection tubes. *Int J Alzheimers Dis* 2012;31:13-20.
50. Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, et al. Impact of harmonization of collection tubes on Alzheimer’s disease diagnosis. *Alzheimers Dement* 2014;10(5 Suppl):S390-S394. e2.
51. Toombs J, Paterson RW, Schott JM, Zetterberg H. Amyloid-beta 42 adsorption following serial tube transfer. *Alzheimers Res Ther* 2014;6:5.
52. Simonsen AH, Rahl JM, Danborg PB, Lindstrom V, Larsen SO, Grubb A, et al. Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. *J Neurosci Methods* 2013;215:234-240.
53. Zimmermann R, Lelental N, Ganslandt O, Maler JM, Kornhuber J, Lewczuk P. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. *J Alzheimers Dis* 2011;25:739-745.
54. Rosenling T, Slim CL, Christin C, Coulier L, Shi S, Stoop MP, et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). *J Proteome Res* 2009; 8:5511-5522.
55. Toombs J, Paterson RW, Lunn MP, Nicholas JM, Fox NC, Chapman MD, et al. Identification of an important potential confound in CSF AD studies: aliquot volume. *Clin Chem Lab Med* 2013;51:2311-2317.
56. Schoonenboom NS, Mulder G, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. *Clin Chem* 2005;51:189-195.
57. Bibl M, Esselmann H, Otto M, Lewczuk P, Cepok L, Rüther E, et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer’s disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. *Electrophoresis* 2004;25:2912-2918.
58. Sjögren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. *Clin Chem* 2001;47:1776-1781.